MIM
IMCR icon

Meridiem Investment Management’s Immunocore IMCR Stock Holding History

Meridiem Investment Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-575
Closed -$19.5K – 68
2024
Q2 		$19.5K Hold
575
– – ﹤0.01% 59
2024
Q1 		$37.4K Hold
575
– – ﹤0.01% 60
2023
Q4 		$39.3K Hold
575
– – ﹤0.01% 71
2023
Q3 		$29.8K Hold
575
– – ﹤0.01% 58
2023
Q2 		$34.5K Hold
575
– – ﹤0.01% 62
2023
Q1 		$28.4K Hold
575
– – ﹤0.01% 63
2022
Q4 		$32.8K Hold
575
– – ﹤0.01% 67
2022
Q3 		$27K Hold
575
– – ﹤0.01% 76
2022
Q2 		$21K Hold
575
– – ﹤0.01% 70
2022
Q1 		$17K Hold
575
– – ﹤0.01% 72
2021
Q4 		$20K Buy
+575
New +$20.8K ﹤0.01% 70

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Meridiem Investment Management's IMCR Position: Q3 2024 in Review

Meridiem Investment Management sold out of Immunocore (IMCR) in Q3 2024, closing a stake of 575 shares — an estimated $19.5K sold.

Meridiem Investment Management first reported a position in IMCR in Q4 2021 and held it in 11 quarters. The position peaked at $39.3K in Q4 2023. 130 funds tracked by Wall St. Rank hold IMCR as of Q3 2024.

  • Meridiem Investment Management reported no remaining Immunocore position as of Q3 2024 after selling out during the quarter.
  • Meridiem Investment Management sold 575 Immunocore shares in Q3 2024, an estimated $19.5K.
  • Meridiem Investment Management first reported a position in Immunocore in Q4 2021 and held it in 11 quarters.
  • Meridiem Investment Management's Immunocore position peaked at $39.3K in Q4 2023.
  • 130 funds tracked by Wall St. Rank held Immunocore as of Q3 2024.

Based on Meridiem Investment Management's 13F filing for Q3 2024, filed 18 Oct 2024.